<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11189" href="/d/html/11189.html" rel="external">see "Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13168" href="/d/html/13168.html" rel="external">see "Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708632"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anti-thymocyte globulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135993"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Thymoglobulin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865950"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Thymoglobulin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F136005"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Immune Globulin;</li>
<li>
                        Immunosuppressant Agent;</li>
<li>
                        Polyclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F135994"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedicate with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion to reduce the incidence and severity of infusion-related reactions. Administer antifungal and antibacterial prophylaxis therapy if clinically indicated. Antiviral prophylaxis is recommended in all patients against herpes simplex virus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30859647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30859647'])">Ref</a></span>) and prophylaxis against cytomegalovirus (CMV) in patients who are CMV-seropositive at the time of transplant and for CMV-seronegative patients scheduled to receive an organ from a CMV-seropositive donor.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b60d588-61ab-4440-9977-e3f50d127245">Graft-versus-host disease, chronic, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, chronic, </b>
<b>prevention (in hematopoietic cell transplantation) (off-label use): IV:</b> 0.5 mg/kg administered 2 days prior to transplant and 2 mg/kg administered 1 day before and 1 day after transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26723083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26723083'])">Ref</a></span>) <b>or</b> 2.5 mg/kg once daily for 3 days beginning 3 days prior to transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23892326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23892326'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e0cffef-d474-4813-8ef4-9a4618957515">Heart transplant, acute cellular rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplant, acute cellular rejection, treatment (off-label use):</b>
<b>IV:</b> 0.75 to 1.5 mg/kg/day for 5 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37080658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37080658'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aff02b67-9324-4417-a75b-a113accddec9">Heart transplant, induction therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplant, induction therapy (in high-risk patients) (off-label use):</b>
<b>IV:</b> 1 to 1.5 mg/kg once daily for up to 7 days; frequency of dosing may be modified based on CD3 count (eg, repeat dose only administered when CD3 count &gt;25 cells/mm<sup>3</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37080658','lexi-content-ref-25363471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37080658','lexi-content-ref-25363471'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c6c4db1-3f3e-44de-8594-c08ba90dbe51">Intestinal and multivisceral transplantation, induction therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intestinal and multivisceral </b>
<b>transplantation, induction therapy (off-label use): IV:</b> 2 mg/kg/day on postoperative days 0, 2, 4, 6, and 8 (in combination with rituximab ± basiliximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18475186','lexi-content-ref-31929425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18475186','lexi-content-ref-31929425'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6bb0376-25a3-4ab1-8a1e-56b30be79a33">Intestinal transplant, acute cellular rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intestinal transplant, acute cellular rejection, treatment (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1.5 mg/kg once daily for 10 to 14 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32882110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32882110'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9205585d-1894-4d35-928e-59f5bee3c00b">Liver transplant, induction therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Liver transplant, induction therapy (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1.5 mg/kg every other day for 2 to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16008596','lexi-content-ref-12717237','lexi-content-ref-34319926','lexi-content-ref-25539464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16008596','lexi-content-ref-12717237','lexi-content-ref-34319926','lexi-content-ref-25539464'])">Ref</a></span>) <b>or </b>1.5 mg/kg once daily for 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31030529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31030529'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0773b36b-fa07-43de-870b-8c08d748af85">Liver transplant, severe acute cellular rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Liver transplant, severe acute cellular rejection, treatment (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen for steroid resistant rejection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 mg/kg to 1.5 mg/kg once daily for 4 to 7 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26052381','lexi-content-ref-27309029','lexi-content-ref-20238251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26052381','lexi-content-ref-27309029','lexi-content-ref-20238251'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19a075c5-2e39-4705-a07d-bfad7412f55a">Kidney transplant, induction therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplant, induction therapy: Note:</b> The manufacturer recommends actual body weight for dosing; however, other strategies have been used. These include ideal body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18497682','lexi-content-ref-26742693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18497682','lexi-content-ref-26742693'])">Ref</a></span>) or cumulative dosing (ie, 5 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26234282','lexi-content-ref-29464204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26234282','lexi-content-ref-29464204'])">Ref</a></span>); refer to center-specific protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 mg/kg/day for 4 to 7 days; the first dose should be administered prior to reperfusion of the donor kidney; the dose and duration may vary depending on concurrent maintenance immunosuppression and patient- and/or allograft-specific variables (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30838775','lexi-content-ref-27223882','lexi-content-ref-19845597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30838775','lexi-content-ref-27223882','lexi-content-ref-19845597'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6243423b-090e-43a8-9115-ac3e43ab5851">Kidney transplant, rejection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Kidney transplant, rejection:</b>
<b>IV:</b> 1.5 mg/kg/day for 7 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a23f8b1b-5a32-4b44-b705-81799ee2fd27">Lung transplant, induction therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lung transplant, induction therapy (off-label use): IV:</b> 1.5 mg/kg/day for 3 days; the first dose was administered within 24 hours of transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18442722','lexi-content-ref-10424515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18442722','lexi-content-ref-10424515'])">Ref</a></span>). Additional trials may be necessary to further define the role of antithymocyte globulin (rabbit) for prevention of rejection after lung transplant.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2726ef1-ed67-4c06-8c16-313cc502ed3d">Lung transplant, persistent acute cellular rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lung transplant, persistent acute cellular rejection, treatment (off-label use): IV:</b> Pulse treatments have been used to manage persistent acute cellular rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20354931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20354931'])">Ref</a></span>). Additional data may be necessary to further define the role of antithymocyte globulin (rabbit) in treatment of acute cellular rejection after lung transplantation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afa510a7-1b61-43a2-8c75-6aae4b9ce8d0">Pancreas transplant, induction therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreas transplant, induction (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 to 1.5 mg/kg once daily or every other day for 3 to 7 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22002345','lexi-content-ref-23183776','lexi-content-ref-18217904','lexi-content-ref-19920781','lexi-content-ref-29738100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22002345','lexi-content-ref-23183776','lexi-content-ref-18217904','lexi-content-ref-19920781','lexi-content-ref-29738100'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c8ab1cc-9742-441b-8157-b67a978420a7">Pancreas transplant, severe acute cellular rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreas transplant, severe acute cellular rejection, treatment (off-label use): Note: </b>Optimal dose, frequency, and duration of therapy have not been established and vary based on institutional protocols. Administer as part of an appropriate combination regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1.5 mg/kg once daily for 5 to 10 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26000231','lexi-content-ref-12372042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26000231','lexi-content-ref-12372042'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991912"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989170"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F26416857"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity: </i>Utilize actual body weight (full weight) to calculate mg/kg dosing for hematopoietic stem cell transplant conditioning regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24462742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24462742'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F639201"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid organ transplantation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">WBC count 2,000 to 3,000 cells/mm<sup>3</sup> or platelet count 50,000 to 75,000 cells/mm<sup>3</sup>: Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">WBC count &lt;2,000 cells/mm<sup>3</sup> or platelet count &lt;50,000 cells/mm<sup>3</sup>: Consider discontinuing or holding dose until counts rebound.</p>
<p style="text-indent:-2em;margin-left:4em;">CD3+ lymphocyte count: Thresholds for discontinuing, holding, or decreasing dose vary based on center-specific protocols; length of CD3 suppression depends on type of organ transplant, concurrent immunosuppression, and other organ function (eg, kidney function); one example of dose adjustment based on CD3 count is to discontinue or hold the dose at a CD3 count &lt;25 cells/mm<sup>3</sup> and redose when CD3 count is &gt;25 cells/mm<sup>3</sup>; these strategies require daily to every-other-day CD3 count monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11981432','lexi-content-ref-12023634','lexi-content-ref-15686739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11981432','lexi-content-ref-12023634','lexi-content-ref-15686739'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F135995"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F136002"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13168" href="/d/html/13168.html" rel="external">see "Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedicate with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion to reduce the incidence and severity of infusion-related reactions. Administer antifungal and antibacterial prophylaxis therapy if clinically indicated. For use in solid organ transplantation (ie, kidney), antiviral prophylaxis is recommended in patients who are CMV-seropositive at the time of transplant and for CMV-seronegative patients scheduled to receive a kidney from a CMV-seropositive donor.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ef8dd22-ff69-4f1b-989a-390250e936b8">Aplastic anemia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aplastic anemia, refractory: </b>Limited data available: Children and Adolescents: IV: 3.5 mg/kg/day once daily for 5 days in combination with cyclosporine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10583220','lexi-content-ref-16704436','lexi-content-ref-23372154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10583220','lexi-content-ref-16704436','lexi-content-ref-23372154'])">Ref</a></span>); <b>Note:</b> Consistent with observations in adult patients, rabbit-antithymocyte globulin is less effective than horse-antithymocyte globulin when either combined with cyclosporine in children and adolescents for initial treatment of severe aplastic anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19673883','lexi-content-ref-21812672','lexi-content-ref-23372153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19673883','lexi-content-ref-21812672','lexi-content-ref-23372153'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7a45e448-c1c0-48f8-ad03-0af9ee6a4c7e">Hematopoietic stem cell transplant; graft-versus-host disease prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant; graft-versus-host disease (GVHD) prevention: </b>Limited data available; regimens and protocols variable; refer to institutional protocols: Infants, Children, and Adolescents: IV: Usual reported TOTAL dose range: 4.5 to 15 mg/kg total divided into 3 to 5 once daily doses administered pretransplant; usual regimen is 3 to 4 doses on consecutive days in combination with chemotherapy or radiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26688094','lexi-content-ref-15753458','lexi-content-ref-16327813','lexi-content-ref-27090956','lexi-content-ref-28705454','lexi-content-ref-24740582','lexi-content-ref-25485863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26688094','lexi-content-ref-15753458','lexi-content-ref-16327813','lexi-content-ref-27090956','lexi-content-ref-28705454','lexi-content-ref-24740582','lexi-content-ref-25485863'])">Ref</a></span>). In adolescents ≥16 years, a lower total dose and timing approach has been successfully used: IV: 0.5 mg/kg/day 2 days before transplantation, 2 mg/kg/day 1 day before transplantation, and 2 mg/kg/day 1 day after transplantation (total dose: 4.5 mg/kg; in addition to standard GVHD prophylaxis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26723083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26723083'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f56a846f-675e-4fee-b8cc-4d0793dd2e36">Solid organ transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid organ transplantation: Note: </b>Doses and timing may vary; refer to institutional specific protocols:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Kidney transplantation: </i>Infant, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction, prophylaxis: IV: 1.5 mg/kg/dose once daily for 4 to 10 doses initiated at time of transplant prior to reperfusion of donor kidney; during variable and dependent on other immunosuppressive regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15849550','lexi-content-ref-20935596']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15849550','lexi-content-ref-20935596'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute rejection, treatment: IV: 1.5 mg/kg/dose once daily for 7 to 14 days</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart/lung transplantation: </i>Limited data available: Infant, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction, prophylaxis: Reported range: IV: 1 to 2 mg/kg/dose once daily infused over 12 hours for 5 days; dose dependent on baseline platelet count; in trials the following doses were used based on platelet count (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12589158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12589158'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;150,000/mm<sup>3</sup>: IV: 2 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:8em;">100,000 to 150,000/mm<sup>3</sup>: IV: 1.5 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:8em;">50,000 to &lt;100,000/mm<sup>3</sup>: IV: 1 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:6em;">Acute rejection, treatment: IV: 2 mg/kg/dose once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12589158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12589158'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Liver, intestinal, or multivisceral transplant</i>: Limited data available: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction, prophylaxis: IV: Total dose of 5 mg/kg divided into separate pre- and post-op doses: 2 to 3 mg/kg over 6 to 8 hours before allograft reperfusion, followed by the remainder 2 to 3 mg/kg over 6 to 8 hours post-operative; used in combination with other immunosuppressives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15868597','lexi-content-ref-15888051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15868597','lexi-content-ref-15888051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Rejection: 1.5 mg/kg/dose once daily; duration variable (usually at least 4 to 5 days) based upon biopsy results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20238251','lexi-content-ref-23925711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20238251','lexi-content-ref-23925711'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084448"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51084449"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F135981"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (18% to 37%), hypotension (10% to 16%), peripheral edema (20%), tachycardia (7% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (12%), diaphoresis (6% to 13%), skin rash (7% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (17% to 57%), hyperlipidemia (15%), hypokalemia (6% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (8% to 38%), constipation (15% to 33%), diarrhea (6% to 20%), nausea (29% to 37%), vomiting (12% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (39% to 42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (12% to 25%), leukocytosis (13%), leukopenia (21% to 63%), thrombocytopenia (9% to 37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cytomegalovirus disease (6% to 13%), infection (17% to 76%; severe infection: 23%), sepsis (6% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (7% to 14%), chills (9% to 57%), headache (18% to 40%), insomnia (12% to 20%), malaise (9% to 13%), pain (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (15%), asthenia (13%), back pain (12%), myalgia (11% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (15% to 28%), lower respiratory tract infection (≤13%), pulmonary disease (12%), upper respiratory tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (13% to 46%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (9%), edema (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (6% to 9%), hyperphosphatemia (6% to 7%), hypophosphatemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (6%), dyspepsia (10%), gastritis (1%), intestinal candidiasis (5%), oral candidiasis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphoproliferative disorder (posttransplant: 2%), malignant neoplasm (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Serum sickness (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (5%), herpes zoster infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (7%), nasopharyngitis (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Miscellaneous: Infusion related reactions</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood, disseminated intravascular coagulation, febrile neutropenia, malignant lymphoma, malignant solid tumor</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, cytokine release syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Reactivation of disease</p></div>
<div class="block coi drugH1Div" id="F135990"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (allergy or anaphylaxis) to rabbit proteins or any component of the formulation; active acute or chronic infection which contraindicate additional immunosuppression</p></div>
<div class="block war drugH1Div" id="F135979"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Reversible leukopenia, neutropenia, thrombocytopenia, and lymphopenia may occur. Monitor blood counts. Leukopenia and/or thrombocytopenia may require dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity and fatal anaphylactic reactions have been reported. Stop infusion immediately if anaphylactic reaction occurs. Immediate treatment (including subcutaneous epinephrine and corticosteroids) should be available during infusion for management of hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Severe infections (bacterial, fungal, viral and/or protozoal) may develop following concomitant use of immunosuppressants with antithymocyte globulin. Reactivation of infections (particularly CMV) and sepsis have been reported. Appropriate antiviral, antibacterial, antiprotozoal, and/or antifungal prophylaxis is recommended. Monitor closely for infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Release of cytokines by activated monocytes and lymphocytes may lead to cytokine release syndrome (CRS) during infusion; may cause serious cardiopulmonary events (sometimes fatal). Rapid infusion rates have been associated with CRS (case reports). Other infusion reaction symptoms, including flu-like symptoms (fever, chills, nausea, muscle/joint pain) may also occur. Local infusion site reactions (pain, swelling, skin redness) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Immunosuppressants, including antithymocyte globulins may increase the incidence of malignancies, including lymphoma, post-transplant lymphoproliferative disease (PTLD) or other malignancies; may be fatal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should not be immunized with attenuated live viral vaccines during or shortly after treatment; safety of immunization following therapy has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Liver transplantation induction: Antithymocyte globulin (rabbit) has been associated with increased adverse effects when used for induction in liver transplantation and should be used cautiously in this population (Boillot 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Initial dose must be administered over at least 6 hours into a high flow vein. Reducing the infusion rate (and prolonging the administration time) may minimize infusion reactions. May pretreat with an antipyretic, antihistamine, and/or corticosteroid.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: <b>[US Boxed Warning]: Should only be used by physicians experienced in immunosuppressive therapy in transplantation.</b> Maintenance immunosuppression may require dosage reduction. Medical surveillance is required during the infusion. Should be administered in combination with other immunosuppressants.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product selection: Antithymocyte globulin (ATG) (rabbit) is available (based on region) in different product formulations, ATG-Thymoglobulin and ATG-Fresenius; the dosing differs among the formulations. Dosing of antithymocyte globulin (rabbit) also differs from dosing of other antithymocyte globulin products (eg, ATG [equine]); protein compositions and concentrations are different. Use caution to ensure dose prescribed is intended for product being administered.</p></div>
<div class="block foc drugH1Div" id="F135985"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thymoglobulin: 25 mg (1 ea) [contains glycine, mannitol, sodium chloride]</p></div>
<div class="block geq drugH1Div" id="F135975"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322995"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Thymoglobulin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1,279.39</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865951"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Thymoglobulin: 25 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F135987"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse the first dose over at least 6 hours; subsequent doses may be infused over at least 4 hours. Infuse through a high-flow vein (central line). Administer through an in-line 0.22 micron filter. Premedication with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to infusion may reduce the incidence and severity of infusion-related reactions. Reducing the infusion rate may minimize infusion reactions. Infusion rate may vary for off-label uses; refer to specific protocol.</p>
<p style="text-indent:-2em;margin-left:2em;">In kidney transplantation, administration through a peripheral vein has been reported with the addition of 1,000 units heparin and 20 mg hydrocortisone (in 500 mL NS only) to decrease the risk of thrombosis and phlebitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12605115','lexi-content-ref-22895613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12605115','lexi-content-ref-22895613'])">Ref</a></span>). The first 2 doses were infused over 6 hours and subsequent doses were infused over 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22895613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22895613'])">Ref</a></span>). Some centers choose not to use additives and administer the dose at a concentration of 1 mg/mL diluted in NS, with the first dose administered over 4 to 6 hours and subsequent doses over 2 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20074083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20074083'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612250"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer by slow IV infusion over 6 to 12 hours for the preconditioning/induction dose or over 6 hours for the initial acute rejection treatment dose; infuse over 4 hours for subsequent doses if first dose tolerated. Administer through an in-line filter with pore size of 0.22 microns via central line or high flow vein. Premedication  with corticosteroids, acetaminophen, and/or an antihistamine may reduce infusion-related reactions.</p></div>
<div class="block use drugH1Div" id="F135986"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplant rejection:</b> Prophylaxis and treatment of acute rejection in kidney transplantation (in conjunction with concomitant immunosuppression).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In a multicenter, double-blind, randomized trial, antithymocyte globulin (rabbit) was shown to be superior to antithymocyte globulin (equine) in reversing acute rejection and preventing subsequent episodes (Gaber 1998). Based on data from studies (including 10 years follow up) comparing ATG (rabbit) to ATG (equine) for induction, ATG (rabbit) has emerged as the T-cell lymphocyte depleting induction therapy of choice over ATG (equine) in adult kidney transplantation due to its improved efficacy and lower incidence of acute rejection (Brennan 1999; Hardinger 2008).</p></div>
<div class="block off-label drugH1Div" id="F25721920"><span class="drugH1">Use: Off-Label: Adult</span><p>Chronic graft-versus-host disease, prevention (in hematopoietic cell transplantation); Heart transplant, acute cellular rejection, treatment; Heart transplant, induction therapy; Intestinal and multivisceral transplantation, induction therapy; Intestinal transplant, acute cellular rejection, treatment; Liver transplant, induction therapy; Liver transplant, severe acute cellular rejection, treatment; Lung transplant, induction therapy; Lung transplant, persistent acute cellular rejection, treatment; Pancreas transplant, induction therapy; Pancreas transplant, severe acute cellular rejection, treatment</p></div>
<div class="block mst drugH1Div" id="F9885364"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Antithymocyte globulin rabbit (Thymoglobulin) may be confused with antithymocyte globulin equine (Atgam)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298764"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218046"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belatacept: Antithymocyte Globulin (Rabbit) may enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased.  Management: A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly. Monitor for venous thrombosis of the renal allograft.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54119851"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of reproductive potential should use effective contraception during and for at least 3 months following treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Antithymocyte globulin (rabbit) has been used as for the induction of immunosuppression in patients undergoing uterine transplant; a minimum interval of 3 months between uterine transplant and embryo transfer is suggested (Johannesson 2019; Jones 2019).</p></div>
<div class="block pri drugH1Div" id="F639176"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Antithymocyte globulin (rabbit) is a purified immunoglobulin G. Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of antithymocyte globulin (rabbit) during pregnancy is limited (Balaha 2019; Kutzler 2016; López 2014; Massenkeil 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Transplant Pregnancy Registry International (TPR) is a registry that follows pregnancies that occur in maternal transplant recipients or those fathered by male transplant recipients. The TPR encourages reporting of pregnancies following solid organ transplant by contacting them at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F21098383"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if antithymocyte globulin (rabbit) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Because other immunoglobulins are present in breast milk, the manufacturer recommends that breastfeeding be discontinued during antithymocyte globulin (rabbit) therapy.</p></div>
<div class="block mop drugH1Div" id="F135983"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Lymphocyte count (total lymphocyte and/or T-cell subset), CBC with differential and platelet count; vital signs during administration; signs and symptoms of infection</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Solid organ transplant:</i> Absolute CD3 count (cells/µL) monitoring and CD3 based dosing has been considered in kidney and heart transplant recipients. It may be beneficial in certain patient populations but is not routinely recommended or utilized. Dose adjustments have been recommended based on the CD3 count (Krasinskas 2002; Peddi 2002; Uber 2004).</p></div>
<div class="block pha drugH1Div" id="F135978"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Antithymocyte globulin (rabbit) is a polyclonal antibody which appears to cause immunosuppression by acting on T-cell surface antigens and depleting CD4 lymphocytes</p></div>
<div class="block phk drugH1Div" id="F135989"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action (T-cell depletion): Within 24 hours (Hardinger 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Lymphopenia may persist for up to 1 year (Hardinger 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2 to 3 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038531"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Atg rabbit</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atg | Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Anti human t lymphocyte rabbit immunoglobulin | Rabbit anti human thymocyte immunoglobulin | Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Timoglobulina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Atg | Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atg | Thymoglobulin | Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobulin | Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Timoglobulina</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Atg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Timoglobulina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Timoglobulina</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Timoglobulina</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atg-Fresenius S | Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobulin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Timoglobulina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Thymoglobuline</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26688094">
<a name="26688094"></a>Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. <i>Lancet Haematol</i>. 2015;2(5):e194-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26688094/pubmed" id="26688094" target="_blank">26688094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30838775">
<a name="30838775"></a>Alloway RR, Woodle ES, Abramowicz D, et al. Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation. <i>Am J Transplant</i>. 2019;19(8):2252-2261. doi:10.1111/ajt.15342<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/30838775/pubmed" id="30838775" target="_blank">30838775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26087667">
<a name="26087667"></a>Ansari D, Lund LH, Stehlik J, et al. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. <i>J Heart Lung Transplant</i>. 2015;34(10):1283-1291. doi:10.1016/j.healun.2015.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26087667/pubmed" id="26087667" target="_blank">26087667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15753458">
<a name="15753458"></a>Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. <i>J Clin Oncol</i>. 2005;23(15):3447-3454.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/15753458/pubmed" id="15753458" target="_blank">15753458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31233481">
<a name="31233481"></a>Aziz F, Parajuli S, Uddin S, et al. How should pancreas transplant rejection be treated?. <i>Transplantation</i>. 2019;103(9):1928-1934. doi:10.1097/TP.0000000000002694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/31233481/pubmed" id="31233481" target="_blank">31233481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30777545">
<a name="30777545"></a>Balaha M, Al-Otaibi T, Gheith OA, et al. Thymoglobulin-resistant t-cell-mediated acute rejection in a pregnant renal transplant recipient: case report and review of the literature. <i>Exp Clin Transplant</i>. 2019;17(Suppl 1):159‐163. doi:10.6002/ect.MESOT2018.P38<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/30777545/pubmed" id="30777545" target="_blank">30777545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33179350">
<a name="33179350"></a>Barros N, Sharfuddin AA, Powelson J, et al. Rabbit anti-thymocyte globulin administration to treat rejection in simultaneous pancreas and kidney transplant recipients with recent COVID-19 infection. <i>Clin Transplant</i>. 2021;35(2):e14149. doi:10.1111/ctr.14149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/33179350/pubmed" id="33179350" target="_blank">33179350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22002345">
<a name="22002345"></a>Bazerbachi F, Selzner M, Boehnert MU, et al. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. <i>Transplantation</i>. 2011;92(9):1039-1043. doi:10.1097/TP.0b013e3182313e4f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/22002345/pubmed" id="22002345" target="_blank">22002345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23183776">
<a name="23183776"></a>Bazerbachi F, Selzner M, Marquez MA, et al. Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. <i>Transplantation</i>. 2013;95(3):489-494. doi:10.1097/TP.0b013e318274ab1a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23183776/pubmed" id="23183776" target="_blank">23183776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16008596">
<a name="16008596"></a>Bogetti D, Sankary HN, Jarzembowski TM, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. <i>Clin Transplant</i>. 2005;19(4):507-511. doi:10.1111/j.1399-0012.2005.00375.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/16008596/pubmed" id="16008596" target="_blank">16008596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19877264">
<a name="19877264"></a>Boillot O, Seket B, Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. <i>Liver Transpl</i>. 2009;15(11):1426-1434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/19877264/pubmed" id="19877264" target="_blank">19877264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15868597">
<a name="15868597"></a>Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J. Evolutionary experience with immunosuppression in pediatric intestinal transplantation. <i>J Pediatr Surg</i>. 2005;40(1):274-279; discussion 279-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/15868597/pubmed" id="15868597" target="_blank">15868597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10221486">
<a name="10221486"></a>Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published correction appears in <i>Transplantation.</i> 1999;67(10):1386]. <i>Transplantation</i>. 1999;67(7):1011-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/10221486/pubmed" id="10221486" target="_blank">10221486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16670072">
<a name="16670072"></a>Broliden PA, Dahl IM, Hast R, et al, “Antithymocyte Globulin and Cyclosporine A as Combination Therapy for Low-Risk Non-Sideroblastic Myelodysplastic Syndromes,” <i>Haematologica</i>, 2006, 91(5):667-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/16670072/pubmed" id="16670072" target="_blank">16670072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12660513">
<a name="12660513"></a>Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. <i>Transplantation</i>. 2003;75(6):844-851.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12660513/pubmed" id="12660513" target="_blank">12660513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10583220">
<a name="10583220"></a>Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Br J Haematol</i>. 1999;107(2):330-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/10583220/pubmed" id="10583220" target="_blank">10583220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12589158">
<a name="12589158"></a>Di Filippo S, Boissonnat P, Sassolas F, et al, “Rabbit Antithymocyte Globulin as Induction Immunotherapy in Pediatric Heart Transplantation,” <i>Transplantation</i>, 2003, 75(3):354-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12589158/pubmed" id="12589158" target="_blank">12589158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25861462">
<a name="25861462"></a>Duhart BT Jr, Ally WA, Krauss AG, et al. The benefit of sirolimus maintenance immunosuppression and rabbit antithymocyte globulin induction in liver transplant recipients that develop acute kidney injury in the early postoperative period. <i>J Transplant</i>. 2015;2015:926168. doi:10.1155/2015/926168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25861462/pubmed" id="25861462" target="_blank">25861462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11510013">
<a name="11510013"></a>Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. <i>Liver Transpl</i>. 2001;7(8):693-697. doi:10.1053/jlts.2001.26353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/11510013/pubmed" id="11510013" target="_blank">11510013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12717237">
<a name="12717237"></a>Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. <i>Transplantation</i>. 2003;75(8):1396-1399. doi:10.1097/01.TP.0000062834.30922.FE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12717237/pubmed" id="12717237" target="_blank">12717237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20074083">
<a name="20074083"></a>Erickson AL, Roberts K, Malek SK, Chandraker AK, Tullius SG, Gabardi S. Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab. <i>Transpl Int</i>. 2010;23(6):636-640. doi:10.1111/j.1432-2277.2009.01042.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/20074083/pubmed" id="20074083" target="_blank">20074083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18217904">
<a name="18217904"></a>Farney A, Sundberg A, Moore P, et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. <i>Clin Transplant</i>. 2008;22(1):41-49. doi:10.1111/j.1399-0012.2007.00742.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18217904/pubmed" id="18217904" target="_blank">18217904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19920781">
<a name="19920781"></a>Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. <i>Transplantation</i>. 2009;88(6):810-819. doi:10.1097/TP.0b013e3181b4acfb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/19920781/pubmed" id="19920781" target="_blank">19920781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29738100">
<a name="29738100"></a>Fridell JA, Mangus RS, Chen JM, et al. Steroid-free three-drug maintenance regimen for pancreas transplant alone: comparison of induction with rabbit antithymocyte globulin +/- rituximab. <i>Am J Transplant</i>. 2018;18(12):3000-3006. doi:10.1111/ajt.14921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/29738100/pubmed" id="29738100" target="_blank">29738100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9679818">
<a name="9679818"></a>Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. <i>Transplantation</i>. 1998;66(1):29-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/9679818/pubmed" id="9679818" target="_blank">9679818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28295952">
<a name="28295952"></a>Garcia Aroz S, Tzvetanov I, Hetterman EA, et al. Long-term outcomes of living-related small intestinal transplantation in children: A single-center experience. <i>Pediatr Transplant</i>. 2017;21(4).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/28295952/pubmed" id="28295952" target="_blank">28295952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31978039">
<a name="31978039"></a>Gondolesi GE. Induction in intestinal transplantation. <i>Transplantation</i>. 2020;104(10):1999-2000. doi:10.1097/TP.0000000000003081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/31978039/pubmed" id="31978039" target="_blank">31978039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18497682">
<a name="18497682"></a>Gurk-Turner C, Airee R, Philosophe B, Kukuruga D, Drachenberg C, Haririan A. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. <i>Transplantation</i>. 2008;85(10):1425-1430. doi:10.1097/TP.0b013e31816dd596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18497682/pubmed" id="18497682" target="_blank">18497682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17125438">
<a name="17125438"></a>Hardinger KL, “Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation,” <i>Pharmacotherapy</i>, 2006, 26(12):1771-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/17125438/pubmed" id="17125438" target="_blank">17125438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18852661">
<a name="18852661"></a>Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. <i>Transplantation</i>. 2008;86(7):947-952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18852661/pubmed" id="18852661" target="_blank">18852661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18442722">
<a name="18442722"></a>Hartwig MG, Snyder LD, Appel JZ 3rd, et al. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. <i>J Heart Lung Transplant</i>. 2008;27(5):547-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18442722/pubmed" id="18442722" target="_blank">18442722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27223882">
<a name="27223882"></a>Hellemans R, Bosmans JL, Abramowicz D. Induction therapy for kidney transplant recipients: do we still need anti-IL2 receptor monoclonal antibodies? <i>Am J Transplant</i>. 2017;17(1):22-27. doi:10.1111/ajt.13884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/27223882/pubmed" id="27223882" target="_blank">27223882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25936966">
<a name="25936966"></a>Hertig A, Zuckermann A. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. <i>Transpl Immunol</i>. 2015;32(3):179-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25936966/pubmed" id="25936966" target="_blank">25936966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15531901">
<a name="15531901"></a>Horan JT, Liesveld JL, Fenton P, et al, “Hematopoietic Stem Cell Transplantation for Multiply Transfused Patients With Sickle Cell Disease and Thalassemia After Low-Dose Total Body Irradiation, Fludarabine, and Rabbit Anti-thymocyte Globulin,” <i>Bone Marrow Transplant</i>, 2005, 35(2):171-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/15531901/pubmed" id="15531901" target="_blank">15531901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16327813">
<a name="16327813"></a>Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. <i>Bone Marrow Transplant</i>. 2006;37(3):263-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/16327813/pubmed" id="16327813" target="_blank">16327813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28295657">
<a name="28295657"></a>Huard G, Schiano TD, Moon J, Iyer K. Severe acute cellular rejection after intestinal transplantation is associated with poor patient and graft survival. <i>Clin Transplant</i>. 2017;31(5):10.1111/ctr.12956. doi:10.1111/ctr.12956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/28295657/pubmed" id="28295657" target="_blank">28295657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915167">
<a name="29915167"></a>Jarmi T, Patel N, Aslam S, et al. Outcomes of induction therapy with rabbit anti-thymocyte globulin in heart transplant recipients: a single center retrospective cohort study. <i>Ann Transplant</i>. 2018;23:422-426. doi:10.12659/AOT.907984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/29915167/pubmed" id="29915167" target="_blank">29915167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31286643">
<a name="31286643"></a>Johannesson L, Wall A, Putman JM, Zhang L, Testa G, Diaz-Garcia C. Rethinking the time interval to embryo transfer after uterus transplantation - DUETS (Dallas UtErus Transplant Study). <i>BJOG</i>. 2019;126(11):1305‐1309. doi:10.1111/1471-0528.15860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/31286643/pubmed" id="31286643" target="_blank">31286643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31410987">
<a name="31410987"></a>Jones BP, Saso S, Bracewell-Milnes T, et al. Human uterine transplantation: a review of outcomes from the first 45 cases. <i>BJOG</i>. 2019;126(11):1310‐1319. doi:10.1111/1471-0528.15863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/31410987/pubmed" id="31410987" target="_blank">31410987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31030529">
<a name="31030529"></a>Jorgenson MR, Descourouez JL, Felix DC, Hanlon BM, Leverson GE, Foley DP. Safety of antithymocyte globulin in patients undergoing liver transplantation with livers from donation after circulatory death donors. <i>Ann Pharmacother</i>. 2019;53(10):981-990. doi:10.1177/1060028019847231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/31030529/pubmed" id="31030529" target="_blank">31030529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27090956">
<a name="27090956"></a>Kang HJ, Hong KT, Lee JW, et al. Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies. <i>Biol Blood Marrow Transplant</i>. 2016;22(8):1455-1459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/27090956/pubmed" id="27090956" target="_blank">27090956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15849550">
<a name="15849550"></a>Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. <i>Transplantation</i>. 2005;79(8):958-963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/15849550/pubmed" id="15849550" target="_blank">15849550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19845597">
<a name="19845597"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant</i>. 2009;9(suppl 3):S1-S155. doi:10.1111/j.1600-6143.2009.02834.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/19845597/pubmed" id="19845597" target="_blank">19845597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11981432">
<a name="11981432"></a>Krasinskas AM, Kreisel D, Acker MA, et al. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. <i>Transplantation</i>. 2002;73(8):1339-1341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/11981432/pubmed" id="11981432" target="_blank">11981432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32882110">
<a name="32882110"></a>Kroemer A, Belyayev L, Khan K, et al. Rejection of intestinal allotransplants is driven by memory T helper type 17 immunity and responds to infliximab. <i>Am J Transplant</i>. 2021;21(3):1238-1254. doi:10.1111/ajt.16283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/32882110/pubmed" id="32882110" target="_blank">32882110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26735993">
<a name="26735993"></a>Kröger N, Solano C, Wolschke C, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>N Engl J Med</i>. 2016;374(1):43-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26735993/pubmed" id="26735993" target="_blank">26735993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26892892">
<a name="26892892"></a>Kutzler HL, Ye X, Rochon C, Martin ST. Administration of antithymocyte globulin (rabbit) to treat a severe, mixed rejection episode in a pregnant renal transplant recipient. <i>Pharmacotherapy</i>. 2016;36(4):e18‐e22. doi:10.1002/phar.1725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26892892/pubmed" id="26892892" target="_blank">26892892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30859647">
<a name="30859647"></a>Lee DH, Zuckerman RA; AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13526. doi:10.1111/ctr.13526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/30859647/pubmed" id="30859647" target="_blank">30859647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27281070">
<a name="27281070"></a>Lee JG, Lee J, Lee JJ, et al. Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation. <i>Medicine (Baltimore)</i>. 2016;95(23):e3711. doi:10.1097/MD.0000000000003711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/27281070/pubmed" id="27281070" target="_blank">27281070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20935596">
<a name="20935596"></a>Li L, Chaudhuri A, Chen A, et al. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. <i>Transplantation</i>. 2010;90(12):1516-1520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/20935596/pubmed" id="20935596" target="_blank">20935596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28705454">
<a name="28705454"></a>Locatelli F, Bernardo ME, Bertaina A, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2017;18(8):1126-1136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/28705454/pubmed" id="28705454" target="_blank">28705454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25420815">
<a name="25420815"></a>López LF, Martínez CJ, Castañeda DA, Hernández AC, Pérez HC, Lozano E. Pregnancy and kidney transplantation, triple hazard? Current concepts and algorithm for approach of preconception and perinatal care of the patient with kidney transplantation. <i>Transplant Proc</i>. 2014;46(9):3027‐3031. doi:10.1016/j.transproceed.2014.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25420815/pubmed" id="25420815" target="_blank">25420815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34732281">
<a name="34732281"></a>Marczin N, de Waal EEC, Hopkins PMA, et al; Task force Chairs and Writing Group (exclusive of the consensus developing and coordinating group members); Consensus Members (exclusive of the consensus developing and coordinating group or co-chairs and writing group members); Independent Reviewers. International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document. <i>J Heart Lung Transplant</i>. 2021;40(11):1327-1348. doi:10.1016/j.healun.2021.07.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/34732281/pubmed" id="34732281" target="_blank">34732281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19673883">
<a name="19673883"></a>Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. <i>Br J Haematol</i>. 2009;147(1):43-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/19673883/pubmed" id="19673883" target="_blank">19673883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20354931">
<a name="20354931"></a>Martinu T, Howell DN, Palmer SM. Acute cellular rejection and humoral sensitization in lung transplant recipients. <i>Semin Respir Crit Care Med</i>. 2010;31(2):179-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/20354931/pubmed" id="20354931" target="_blank">20354931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12605115">
<a name="12605115"></a>Marvin MR, Droogan C, Sawinski D, Cohen DJ, Hardy MA. Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients. <i>Transplantation</i>. 2003;75(4):488-489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12605115/pubmed" id="12605115" target="_blank">12605115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27522225">
<a name="27522225"></a>Massenkeil G, Alexander T, Rosen O, et al. Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation. <i>Rheumatol Int</i>. 2016;36(11):1563‐1568. doi:10.1007/s00296-016-3531-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/27522225/pubmed" id="27522225" target="_blank">27522225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26052381">
<a name="26052381"></a>Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. <i>World J Hepatol</i>. 2015;7(10):1355-1368. doi:10.4254/wjh.v7.i10.1355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26052381/pubmed" id="26052381" target="_blank">26052381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27309029">
<a name="27309029"></a>Montenovo MI, Jalikis FG, Li M, et al. Superior patient and graft survival in adult liver transplant with rabbit antithymocyte globulin induction: experience with 595 patients. <i>Exp Clin Transplant</i>. 2017;15(4):425-431. doi:10.6002/ect.2015.0350<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/27309029/pubmed" id="27309029" target="_blank">27309029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34319926">
<a name="34319926"></a>Nair A, Coromina Hernandez L, Shah S, et al. Induction therapy with antithymocyte globulin and delayed calcineurin inhibitor initiation for renal protection in liver transplantation: a multicenter randomized controlled phase II-B trial. <i>Transplantation</i>. 2022;106(5):997-1003. doi:10.1097/TP.0000000000003904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/34319926/pubmed" id="34319926" target="_blank">34319926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10424515">
<a name="10424515"></a>Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. <i>Chest</i>. 1999;116(1):127-133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/10424515/pubmed" id="10424515" target="_blank">10424515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30577245">
<a name="30577245"></a>Palmer WC, Taner CB, Keaveny AP, Nakhleh RE, Nguyen JH, Rosser BG Jr. Antithymocyte globulin use for corticosteroid nonresponsive rejection after liver transplantation. <i>Transplant Proc</i>. 2018;50(10):3606-3614. doi:10.1016/j.transproceed.2018.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/30577245/pubmed" id="30577245" target="_blank">30577245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12023634">
<a name="12023634"></a>Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. <i>Transplantation</i>. 2002;73(9):1514-1518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12023634/pubmed" id="12023634" target="_blank">12023634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26234282">
<a name="26234282"></a>Pennington CA, Tischer SM, Lee E, Lee S, Sindelar J Jr, Park JM. Evaluation of a weight-based rabbit anti-thymocyte globulin induction dosing regimen for kidney transplant recipients. <i>Pharmacotherapy</i>. 2015;35(8):748-754. doi:10.1002/phar.1624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26234282/pubmed" id="26234282" target="_blank">26234282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26000231">
<a name="26000231"></a>Redfield RR, Kaufman DB, Odorico JS. Diagnosis and treatment of pancreas rejection. <i>Curr Transplant Rep</i>. 2015;2(2):169-175. doi:10.1007/s40472-015-0061-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26000231/pubmed" id="26000231" target="_blank">26000231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15888051">
<a name="15888051"></a>Reyes J, Mazariegos GV, Abu-Elmagd K, et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). <i>Am J Transplant</i>. 2005;5(6):1430-1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/15888051/pubmed" id="15888051" target="_blank">15888051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23892326">
<a name="23892326"></a>Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplant</i>. 2014;49(2):168-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23892326/pubmed" id="23892326" target="_blank">23892326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25013609">
<a name="25013609"></a>Saidi RF, Hertl M, Chung RT, et al. Induction with rabbit antithymocyte globulin following orthotopic liver transplantation for Hepatitis C. <i>Int J Organ Transplant Med</i>. 2011;2(4):160-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25013609/pubmed" id="25013609" target="_blank">25013609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21812672">
<a name="21812672"></a>Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. <i>N Engl J Med</i>. 2011;365(5):430-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/21812672/pubmed" id="21812672" target="_blank">21812672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16704436">
<a name="16704436"></a>Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. <i>Br J Haematol</i>. 2006;133(6):622-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/16704436/pubmed" id="16704436" target="_blank">16704436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20238251">
<a name="20238251"></a>Schmitt TM, Phillips M, Sawyer RG, et al. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. <i>Dig Dis Sci</i>. 2010;55(11):3224-3234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/20238251/pubmed" id="20238251" target="_blank">20238251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29464204">
<a name="29464204"></a>Singh N, Rossi AP, Savic M, Rubocki RJ, Parker MG, Vella JP. Tailored rabbit antithymocyte globulin induction dosing for kidney transplantation. <i>Transplant Direct</i>. 2018;4(2):e343. doi:10.1097/TXD.0000000000000765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/29464204/pubmed" id="29464204" target="_blank">29464204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17600336">
<a name="17600336"></a>Soliman T, Hetz H, Burghuber C, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. <i>Liver Transpl</i>. 2007;13(7):1039-1044. doi:10.1002/lt.21185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/17600336/pubmed" id="17600336" target="_blank">17600336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24740582">
<a name="24740582"></a>Soni S, Gross TG, Rangarajan H, Baker KS, Sturm M, Rhodes M. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin. <i>Pediatr Blood Cancer</i>. 2014;61(9):1685-1689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/24740582/pubmed" id="24740582" target="_blank">24740582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12737859">
<a name="12737859"></a>Starzl TE, Murase N, Abu-Elmagd K, et al, “Tolerogenic Immunosuppression for Organ Transplantation,” <i>Lancet</i>, 2003, 361(9368):1502-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12737859/pubmed" id="12737859" target="_blank">12737859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11726830">
<a name="11726830"></a>Stegall MD, Kim DY, Prieto M, et al. Thymoglobulin induction decreases rejection in solitary pancreas transplantation. <i>Transplantation</i>. 2001;72(10):1671-1675. doi:10.1097/00007890-200111270-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/11726830/pubmed" id="11726830" target="_blank">11726830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23372154">
<a name="23372154"></a>Takahashi Y, Muramatsu H, Sakata N, et al. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia. <i>Blood</i>. 2013;121(5):862-863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23372154/pubmed" id="23372154" target="_blank">23372154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23925711">
<a name="23925711"></a>Thangarajah D, O'Meara M, Dhawan A. Management of acute rejection in paediatric liver transplantation. <i>Paediatr Drugs</i>. 2013;15(6):459-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23925711/pubmed" id="23925711" target="_blank">23925711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thymoglobulin.1">
<a name="Thymoglobulin.1"></a>Thymoglobulin (anti-thymocyte globulin [rabbit]) [prescribing information]. Cambridge, MA: Genzyme Corporation; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23026616">
<a name="23026616"></a>Trevizol AP, David AI, Dias ER, Mantovani D, Pécora R, D'Albuquerque LA. Intestinal and multivisceral transplantation immunosuppression protocols--literature review. <i>Transplant Proc</i>. 2012;44(8):2445-2448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23026616/pubmed" id="23026616" target="_blank">23026616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12966908">
<a name="12966908"></a>Trissel LA and Saenz CA, “Physical Compatibility of Antithymocyte Globulin (Rabbit) With Heparin Sodium and Hydrocortisone Sodium Succinate,” <i>Am J Health Syst Pharm</i>, 2003, 60(16):1650-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12966908/pubmed" id="12966908" target="_blank">12966908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22895613">
<a name="22895613"></a>Trofe-Clark J, Reese PP, Patel HJ, et al. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes. <i>Transplantation</i>. 2012;94(5):506-512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/22895613/pubmed" id="22895613" target="_blank">22895613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12372042">
<a name="12372042"></a>Trofe J, Stratta RJ, Egidi MF, et al. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience. <i>Clin Transplant</i>. 2002;16(suppl)7:34-44. doi:10.1034/j.1399-0012.16.s7.5.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/12372042/pubmed" id="12372042" target="_blank">12372042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15686739">
<a name="15686739"></a>Uber WE, Uber LA, VanBakel AB, et al. CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. <i>Transplant Proc</i>. 2004;36(10):3245-3249. doi:10.1016/j.transproceed.2004.11.099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/15686739/pubmed" id="15686739" target="_blank">15686739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26742693">
<a name="26742693"></a>Vacha M, Gommer J, Rege A, Sanoff S, Sudan D, Harris M. Effects of ideal versus total body weight dosage of rabbit antithymocyte globulin on outcomes of kidney transplant patients with high immunologic risk. <i>Exp Clin Transplant</i>. 2016;14(5):511-517. doi:10.6002/ect.2015.0197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26742693/pubmed" id="26742693" target="_blank">26742693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31929425">
<a name="31929425"></a>Vianna R, Farag A, Gaynor JJ, et al. Association of more intensive induction with less acute rejection following intestinal transplantation: results of 445 consecutive cases from a single center. <i>Transplantation</i>. 2020;104(10):2166-2178. doi:10.1097/TP.0000000000003074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/31929425/pubmed" id="31929425" target="_blank">31929425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18475186">
<a name="18475186"></a>Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. <i>Transplantation</i>. 2008;85(9):1290-1293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/18475186/pubmed" id="18475186" target="_blank">18475186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26723083">
<a name="26723083"></a>Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncol</i>. 2016;17(2):164-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/26723083/pubmed" id="26723083" target="_blank">26723083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25284138">
<a name="25284138"></a>Whitson BA, Kilic A, Lehman A, et al. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents. <i>Clin Transplant</i>. 2015;29(1):9-17. doi:10.1111/ctr.12469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25284138/pubmed" id="25284138" target="_blank">25284138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25485863">
<a name="25485863"></a>Willemsen L, Jol-van der Zijde CM, Admiraal R, et al. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. <i>Biol Blood Marrow Transplant</i>. 2015;21(3):473-482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25485863/pubmed" id="25485863" target="_blank">25485863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25539464">
<a name="25539464"></a>Yoo MC, Vanatta JM, Modanlou KA, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction in 500 consecutive patients. <i>Transplantation</i>. 2015;99(6):1231-1235. doi:10.1097/TP.0000000000000477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25539464/pubmed" id="25539464" target="_blank">25539464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23372153">
<a name="23372153"></a>Yoshimi A, Niemeyer CM, Führer MM, Strahm B. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children. <i>Blood</i>. 2013;121(5):860-861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/23372153/pubmed" id="23372153" target="_blank">23372153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25363471">
<a name="25363471"></a>Zuckermann A, Schulz U, Deuse T, et al. Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. <i>Transpl Int</i>. 2015;28(3):259-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/antithymocyte-globulin-rabbit-derived-thymoglobulin-drug-information/abstract-text/25363471/pubmed" id="25363471" target="_blank">25363471</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10026 Version 238.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
